AU5358494A - Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein - Google Patents

Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein

Info

Publication number: AU5358494A
Authority: AU; Australia
Prior art keywords: amyloid; protein; beta; inhibiting binding; precursor protein
Prior art date: 1992-10-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU53584/94A

Inventor

Warren J Strittmatter

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Duke University

Original Assignee

Duke University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-10-13

Filing date

1993-10-13

Publication date

1994-05-09

1993-10-13 Application filed by Duke University filed Critical Duke University

1994-05-09 Publication of AU5358494A publication Critical patent/AU5358494A/en

Status Abandoned legal-status Critical Current

Links

102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
101710137189 Amyloid-beta A4 protein Proteins 0.000 title 1
101710151993 Amyloid-beta precursor protein Proteins 0.000 title 1
102100022704 Amyloid-beta precursor protein Human genes 0.000 title 1
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Microbiology (AREA)
Pathology (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Neurosurgery (AREA)
Peptides Or Proteins (AREA)

AU53584/94A 1992-10-13 1993-10-13 Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein Abandoned AU5358494A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US95925192A	1992-10-13	1992-10-13
US959251		1992-10-13
PCT/US1993/009772 WO1994009364A1 (en)	1992-10-13	1993-10-13	Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein

Publications (1)

Publication Number	Publication Date
AU5358494A true AU5358494A (en)	1994-05-09

Family

ID=25501838

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU53584/94A Abandoned AU5358494A (en)	1992-10-13	1993-10-13	Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein

Country Status (2)

Country	Link
AU (1)	AU5358494A (en)
WO (1)	WO1994009364A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5780587A (en) *	1990-08-24	1998-07-14	President And Fellows Of Harvard College	Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
AU7664296A (en) *	1995-11-02	1997-05-22	Warner-Lambert Company	Naphthylazo inhibition of amyloidosis
WO1998037421A1 (en) *	1997-02-19	1998-08-27	Regents Of The University Of Minnesota	Aβ DEPOSITION INHIBITOR SCREEN USING SYNTHETIC AMYLOID
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
WO2000043791A2 (en)	1999-01-25	2000-07-27	Minerva Biotechnologies Corporation	Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases
US6017913A (en) *	1999-05-03	2000-01-25	Warner-Lambert Company	Naphthylazo inhibition of amyloidosis
PE20020574A1 (en)	2000-12-06	2002-07-02	Wyeth Corp	HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
PE20050627A1 (en)	2003-05-30	2005-08-10	Wyeth Corp	HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
PE20061329A1 (en)	2004-12-15	2006-12-08	Neuralab Ltd	HUMANIZED AB ANTIBODIES TO IMPROVE COGNITION
US7625560B2 (en)	2004-12-15	2009-12-01	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
SI2182983T1 (en)	2007-07-27	2014-09-30	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	Immunotherapy regimes dependent on apoe status
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
ES2951901A1 (en) *	2022-03-17	2023-10-25	Univ Miguel Hernandez De Elche	METHOD AND DIAGNOSIS KIT OF ALZHEIMER'S DISEASE BASED ON THE DETECTION OF APOLIPOPROTEIN E (Machine-translation by Google Translate, not legally binding)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4923901A (en) *	1987-09-04	1990-05-08	Millipore Corporation	Membranes with bound oligonucleotides and peptides
WO1992003474A1 (en) *	1990-08-24	1992-03-05	President And Fellows Of Harvard College	METHOD OF INTERFERING WITH FORMATION OF α-ANTICHYMOTRYPSIN-β-PROTEIN COMPLEX AND SYNTHETIC PEPTIDES FOR USE THEREIN

1993
- 1993-10-13 AU AU53584/94A patent/AU5358494A/en not_active Abandoned
- 1993-10-13 WO PCT/US1993/009772 patent/WO1994009364A1/en not_active Ceased

Also Published As

Publication number	Publication date
WO1994009364A1 (en)	1994-04-28

Publication	Publication Date	Title
AU5358494A (en)	1994-05-09	Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein
AU649711B2 (en)	1994-06-02	Method of purifying bisphenol-A
AU5803394A (en)	1994-07-04	Mechanized directory assistance
AU5898586A (en)	1987-01-08	Filtration of beer
AU580820B2 (en)	1989-02-02	Treatment of obesity
AU5044393A (en)	1994-05-19	Stereoselective reduction of ketones
AU5218593A (en)	1994-07-07	Method of milling
AU7412196A (en)	1997-06-12	5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of beta-amyloid protein production
AU2872795A (en)	1996-02-22	Inhibition of platelet binding
AU2895192A (en)	1994-05-24	Substances having the growth-promoting effect of amyloid precursor protein
AU3730093A (en)	1993-09-13	Methods of treating diabetes
AU4220193A (en)	1993-11-29	Deazaaminopterins for treatment of inflammation
AU4805093A (en)	1994-06-22	Methods for treatment of enzyme preparations
IL85911A (en)	1993-05-13	Substituted aromatic silane compounds and method for preparation of same
AU7822394A (en)	1995-05-04	Fimbrillin protein of porphyromonas gingivalis
AU673961B2 (en)	1996-11-28	Methods of inhibiting the effects of amyloidogenic proteins
AU5149793A (en)	1994-05-09	Method of preparing aminoalkylhydantoins and aminoalkyl-alpha-aminoacids
AU4268793A (en)	1993-11-29	Method of casting
AU4119993A (en)	1993-11-29	Heteroaroyl-10-deazaaminopterins for treatment of inflammation
RU2003311C1 (en)	1993-11-30	Method of blepharorrhaphy
AU5719494A (en)	1994-06-22	Method of preparing sulfur-containing compounds
AU1619688A (en)	1988-08-25	Method of construction
AU4223289A (en)	1990-03-23	Treatment of metal slabs
AU6802794A (en)	1994-12-20	Inhibitors of nef-cd4 binding
GB2291056B (en)	1998-06-24	Method of separating meta-and para-ethylphenol